

**HAI DUONG PHARMACEUTICAL
MEDICAL MATERIALS JSC.**

**SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom - Happiness**

No: 869/2026-CV

Hai Phong, July 22nd, 2026

*Re: Explanation for the change exceeding
10% in post-tax profit for the second quarter
of 2026*

To: - State Securities Commission of Vietnam
- Hanoi Stock Exchange

- **Company Name:** Hai Duong Pharmaceutical Medical Materials Joint Stock Company
- **Enterprise Registration Certificate No.:** 0800011018
- **Head Office:** 102 Chi Lang Street – Thanh Dong Ward – Hai Phong City – Viet Nam
- **Telephone:** 0220 385 3848 **Fax:** 0220 385 3848

Pursuant to Clause 4, Article 14 of Circular No. 96/2020/TT-BTC dated November 16th, 2020 issued by the Ministry of Finance guiding information disclosure on the securities market, Hai Duong Pharmaceutical Medical Materials Joint Stock Company hereby provides the following explanation regarding the financial statements for the second quarter of 2026:

1. Post-tax Profit:

According to the second quarter of 2026 financial statements, the company's post-tax profit increased by **32,9%** compared to the same period in 2025. Details are as follows:

Unit: VND

Indicator	The second quarter of 2026	The second quarter of 2025	% Increase
Profit after corporate income tax	15.774.787.752	11.868.633.515	32,9%

Explanation:

- Revenue for the second quarter of 2026 increased by 7.4% compared to the same period in 2025, which led to a corresponding increase in gross profit.
- The proportion of revenue from manufactured goods in total sales for second quarter of 2026 increased from 82.4% to 83.5% (a rise of 1.1%), which led to an increase in the average gross profit margin from 36.6% in the second quarter of 2025 to 37.5% in the second quarter of 2026 (a difference of 0.9%).
- The increase in average revenue and gross profit margin during the second quarter of 2026 led to an additional gross profit of VND 5,976,182,670, equivalent to a 10% increase. This was the main driver behind the growth in profit before corporate income tax (CIT).
- Financial expenses, administrative and selling expenses in the second quarter of 2026 were well-managed. Although these costs increased, their growth rate was lower than that of gross profit, contributing further to the rise in post-tax profit.



Based on the reasons above, the company's post-tax profit for the second quarter of 2026 increased compared to the second quarter of 2025.

The complete the second quarter of 2026 financial statements have been published on the company's website: hdpharma.vn

We hereby certify that the information disclosed above is true and that we shall take full legal responsibility for its content.

Recipients:

- As above
- Company archives

**HAI DUONG PHARMACEUTICAL MEDICAL MATERIAL
JOINT STOCK COMPANY
GENERAL DIRECTOR**



**TỔNG GIÁM ĐỐC
ĐSCK I: NGUYỄN THỊ TÚ ANH**

